Skip to main content
Fig. 1 | Clinical Proteomics

Fig. 1

From: Glycoproteomics revealed novel N-glycosylation biomarkers for early diagnosis of lung adenocarcinoma cancers

Fig. 1

Workflow of N-glycosylation analysis in LUAD patients and NL controls. Trypsin was added into all samples for protein digestion and then processed by TMT kit/iTRAQ kit. High pH reverse-phase HPLC was performed to fractionate tryptic peptides and then dissolved in NETN buffer for enrichment. The peptides were then subjected to tandem mass spectrometry (LC–MS/MS) in Q ExactiveTM Plus. A data-dependent procedure was then conducted to peptides and alternated between one MS scan followed by 20 LC–MS/MS scans with 15.0 s dynamic exclusion

Back to article page

Clinical Proteomics

ISSN: 1559-0275